Cargando…
Clinical Outcome After Discontinuation of Anticoagulation Therapy in Japanese Patients With Venous Thromboembolism ― Insights From the J’xactly Study ―
Background: Rivaroxaban, a direct oral anticoagulant, is used as first-line treatment to prevent venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). However, the frequency of rivaroxaban discontinuation and the subsequent clinical outcomes remain unclear....
Autores principales: | Yamashita, Takeshi, Fukuda, Ikuo, Nakamura, Mashio, Yamada, Norikazu, Takayama, Morimasa, Maeda, Hideaki, Ikeda, Takanori, Mo, Makoto, Yamazaki, Tsutomu, Okumura, Yasuo, Hirayama, Atsushi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Circulation Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360983/ https://www.ncbi.nlm.nih.gov/pubmed/36032386 http://dx.doi.org/10.1253/circrep.CR-22-0011 |
Ejemplares similares
-
Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
por: Migita, Shohei, et al.
Publicado: (2023) -
Duration of Initial Intensive Rivaroxaban Therapy for Patients With Venous Thromboembolism ― Subanalysis of the J’xactly Study ―
por: Nakamura, Mashio, et al.
Publicado: (2023) -
Rivaroxaban Treatment for Patients With Unprovoked or Provoked Venous Thromboembolism ― Subanalysis of the J’xactly Study ―
por: Hisatake, Shinji, et al.
Publicado: (2022) -
Prognostication of Patients with Pulmonary Thromboembolism with and without Residual Deep Vein Thrombosis: A Subanalysis of the J’xactly Study
por: Yamada, Norikazu, et al.
Publicado: (2023) -
Relationship between baseline D-dimer and prognosis in Japanese patients with venous thromboembolism: Insights from the J’xactly study
por: Migita, Shohei, et al.
Publicado: (2023)